Tudor Investment Corp ET AL Invests $151,000 in Collegium Pharmaceutical, Inc. (COLL)

Tudor Investment Corp ET AL bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $151,000. Tudor Investment Corp ET AL owned approximately 0.05% of Collegium Pharmaceutical at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. American International Group Inc. boosted its position in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Nationwide Fund Advisors boosted its position in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the period. Macquarie Group Ltd. acquired a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $127,000. UBS Group AG boosted its position in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Collegium Pharmaceutical during the first quarter valued at approximately $238,000. Institutional investors own 82.13% of the company’s stock.

Collegium Pharmaceutical, Inc. (COLL) opened at 10.07 on Friday. The company’s 50-day moving average price is $11.86 and its 200 day moving average price is $11.76. The company’s market capitalization is $297.73 million. Collegium Pharmaceutical, Inc. has a 52 week low of $7.37 and a 52 week high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post ($3.00) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/15000-shares-in-collegium-pharmaceutical-inc-coll-acquired-by-tudor-investment-corp-et-al-updated-updated.html.

COLL has been the subject of several research analyst reports. Janney Montgomery Scott reiterated a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. Jefferies Group LLC restated a “buy” rating and set a $22.00 price objective (down from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Finally, Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $21.33.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit